MYL - Mylan N.V. Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 NVDA (0.15%) BAC (-0.03%) SPWR (-0.23%) TLRY (2.65%) TVIX (0.16%) UGAZ (-9.35%) PTON (2.83%) AZO (1.1%) APA (-1.3%) AMZN (-0.71%) AAPL (1.11%) NOG (-3.58%) NK (-0.41%) NBEV (1.55%) MDGL (-0.4%) JMIA (-6.59%) JD (2%) INPX (-6.81%) IBM (0.24%) GS (-0.11%) GILD (-0.35%) FTSV (11.16%) FSLR (-0.76%) FB (0.17%) EYEG (-9.87%)

MYL - Mylan N.V.

$21.66 -0.31[-1.42%]

15 mins delayed data

People also watch : SNY | PFE | LCI | TEVA | RDY

+Watchlist

6 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$21.97	Open	$22.02
Volume	6.4M	Market Cap	8.871B
Yield		Last Dividend

Day

52 Week

Three more heartburn drugs recalled over...	01/10/20
This week, the FDA announced recalls of Zantac generics made by Appco Pharma, Northwind and Mylan's non-ranitidine heartburn drug nizatdine. A Califor...

Viatris Will Be the New Kid in Generic D...	01/09/20
Pfizer???s legacy-drug business Upjohn will merge with the generic-drug company Mylan to create a new company called Viatris this year. Piper Sandler ...

Mylan Initiates Voluntary Nationwide Rec...	01/08/20
HERTFORDSHIRE, England, and PITTSBURGH, Jan. 8, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceutical...

True North to invest Rs 536.25 crore in ...	01/06/20
Biocon Biologics has a product pipeline of 28 molecules, including 11 with Mylan, several with Sandoz, and is developing many independently.

Is Mylan (MYL) Doomed to Witness a Terri...	12/27/19
As Mylan (MYL) remained plagued with challenges in 2019, we take an insight into whether or not, the next year holds any promise for the company.

Shareholder Alert: Robbins LLP Announces...	12/20/19
SAN DIEGO & HERTFORDSHIRE, England--(BUSINESS WIRE)---- $MYL #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Mylan...

MYL INVESTOR ALERT: Bernstein Liebhard L...	12/19/19
NEW YORK, Dec. 19, 2019 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action ...

Global Heart Transplantation Therapeutic...	12/13/19
LONDON--(BUSINESS WIRE)-- #Biotechnology--The global heart transplantation therapeutics market is poised to grow by USD 94.37 million during 2020-2024...

Why Is Mylan (MYL) Up 10% Since Last Ear...	12/05/19
Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here is What Hedge Funds Think About Myl...	12/04/19
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, ...

ANALYST RATINGS

5 analyst ratings (Last 6 months)

60.00 %

Strong Buy + Buy

Price Target (PT)

Strong Buy rating	01/07/20
RBC Capital maintains Outperform rating and raises Price Target from $25.00 to $27.00

Hold rating	11/07/19
JP Morgan downgrades from Overweight to Equal-Weight rating and lowers Price Target from $25.00 to $18.00

Hold rating	11/07/19
Morgan Stanley downgrades from Overweight to Equal-Weight rating and lowers Price Target from $25.00 to $18.00

Buy rating	09/12/19
SunTrust Robinson Humphrey maintains Buy rating and raises Price Target from $25.00 to $27.00

Strong Buy rating	07/30/19
and raises Price Target from $22.00 to $25.00

EARNINGS

Date	2019-11-05 (AMC)	Est. (EPS/Rev.)	$1.13/ 3.01B
Actual (EPS/Rev.)	$1.17/ $2.96 B	EPS (TTM)	0

TRADERS TRACKING $MYL

Service Name	Trader	% Success
The profit machine	Gino Baldassano	70.00 %	Follow
Alpha Swing Trades	Jonathan	69.00 %	Follow
TopFlight Trades - Premium (Options)	Eric Cunningham	50.00 %	Follow
Options Mann	Thomas Mann	40.00 %	Follow
Symmetry Options	Symmetry Options	33.00 %	Follow

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Follow Us

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.